Payment overview · 2025
General Payments
$1,355.86
54 reported records · 19 companies
Healthcare provider profile · identity verified
Fanny Siman Lean Ho
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GARLAND, TX · NPI 1649774183
Verified facts
What the public records show
CMS Open Payments records show Fanny Siman Lean Ho received $1,355.86 in general payments during 2025 across 54 reported records.
Abbott Laboratories accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $267.95 | 19.8% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.08 | 12.8% | 8 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$170.68 | 12.6% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $135.13 | 10.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $124.86 | 9.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.66 | 6.7% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.68 | 5.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.59 | 4.5% | 3 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $48.33 | 3.6% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $39.23 | 2.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.97 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.76 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.54 | 1.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.42 | 1.5% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $20.02 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.92 | 1.5% | 1 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $18.80 | 1.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.09 | 1.3% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $7.15 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,355.86 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $267.95 | 9 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $170.68 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $135.13 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $124.86 | 4 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $90.66 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.02 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $71.68 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.30 | 3 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $48.33 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $7.15 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $7.15 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $7.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 314 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 92 |
| Lisinopril | Lisinopril | 220 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 89 |
| Losartan Potassium | Losartan Potassium | 146 | 60 |
| Gabapentin | Gabapentin | 136 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 47 |
| Metformin Hcl | Metformin Hcl | 123 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 44 |
| Alendronate Sodium | Alendronate Sodium | 87 | 37 |
| Omeprazole | Omeprazole | 81 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 77 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 32 |
| Furosemide | Furosemide | 74 | 28 |
| Carvedilol | Carvedilol | 63 | 29 |
| Ezetimibe | Ezetimibe | 62 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 25 |
| Famotidine | Famotidine | 59 | 31 |
| Metformin Hcl Er | Metformin Hcl | 56 | 25 |
| Trazodone Hcl | Trazodone Hcl | 56 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 32 |
| Simvastatin | Simvastatin | 50 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 22 |
| Ozempic | Semaglutide | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 21 |
| Finasteride | Finasteride | 42 | 22 |
| Montelukast Sodium | Montelukast Sodium | 42 | 20 |
| Meloxicam | Meloxicam | 41 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 19 |
| Buspirone Hcl | Buspirone Hcl | 31 | 15 |
| Eliquis | Apixaban | 31 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Farxiga | Dapagliflozin Propanediol | 26 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | 14 |
| Nifedipine Er | Nifedipine | 24 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 16 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | 14 |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | 13 |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | 12 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Ciclopirox | Ciclopirox Olamine | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,355.86 · 54 records | Abbott Laboratories | AFREZZA, CYCLOSET, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Flector, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, Licart, MINIMED 780G, MOUNJARO, Omnipod, Ozempic, REZDIFFRA, Rybelsus, TEPEZZA, TZIELD, Tirosint, Veozah, Wegovy, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error